EFFECTIVENESS OF EXTRACORPOREAL SHOCK-WAVE THERAPY(ESWT) IN PATIENTS WITH BREAST CANCER-RELATED LYMPHEDEMA
The aim of this study is to evaluate the effectiveness of extracorporeal shock wave therapy (ESWT) combined with complete decongestive therapy (CDT) compared with CDT alone in patients with breast cancer-related lymphedema. Female patients with unilateral Stage II upper-extremity lymphedema related to breast cancer will be included. Participants will receive either complete decongestive therapy alone or complete decongestive therapy combined with extracorporeal shock wave therapy. Clinical outcomes will be evaluated before treatment, immediately after treatment, and at 1 and 3 months after treatment. Primary outcomes will include limb circumference difference, volumetric measurements, and ultrasonographic assessment of skin and subcutaneous tissue thickness. Secondary outcomes will include upper-extremity function, quality of life, and pain.
• At least 2 years have elapsed since the diagnosis of breast cancer, cancer treatment has been completed, and cure has been documented during oncology follow-up.
• Stage II lymphedema according to the International Society of Lymphology classification.
• Duration of lymphedema of less than 4 years.
• Voluntary participation in the study. -